Frequency Of Eye Problems In Type 2 Diabetes With Chronic Kidney Disease

NCT ID: NCT03330054

Last Updated: 2017-11-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-12-01

Study Completion Date

2018-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluate the frequency and type of eye problem among Type 2 Diabetics with renal impairment and effect of renal impairment and haemodialysis on diabetic retinopathy

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chronic kidney disease is a descriptive term and is used for deteriorating kidney function of any underlying cause. Chronic kidney disease implies longstanding (\>3 months), potentially progressive, impairment in renal function.(Kumar \& Clark's ., 2016).

Diabetes mellitus is the most common cause of chronic kidney disease in developed countries. In patients with diabetes, there is a steady advance from microalbuminuria to dipstick positive proteinuria and a progression to renal failure. (Davidson's.,2014) .The most commonly diagnosed diabetes-related complications is diabetic retinopathy. Its prevalence increases with the duration of diabetes. Some 20%of people with type 1 diabetes will have retinal changes after 10 years, rising to \>95% after20 years; 20-30% of people with type 2 diabetes have retinopathy at diagnosis.(Kumar \& Clark's ., 2016) .

Also from risk factors of diabetic retinopathy is nephropathy, and if severe, is associated with worsening of Diabetic retinopathy. Conversely, treatment of renal disease (e.g. renal transplantation) may be associated with improvement of retinopathy and a better response to photocoagulation.(Kanaski ,2016) The high burden of ocular disease in Chronic kidney disease can be explained, in part, by the sharing of risk factors common to both kidney and eye diseases such as age, smoking, hypertension, diabetes, raised serum cholesterol and obesity. Ocular diseases may also be directly linked to chronic kidney disease via common pathogenic pathways, including, atherosclerosis, microangiopathy, inflammation and oxidative stress (Wong et al., 2014).

In our study we seek to do the following for participants :

1. A detailed history including

1. Age, sex, smoking Habits
2. Duration of diabetes mellitus and treatment.
3. Chronic kidney disease stage by estimated glomerular filtration rate according to MDRD formula
4. Duration of haemodialysis.
5. Associated co-morbidity as hypertension,
6. Therapeutic history eg; angiotensin converting enzyme, angiotensin II receptor blocker, amiodarone, erythropoietin.
2. Complete Clinical examination including haemodynamics, complete cardiac, chest, abdominal, lower limb examination, cranial nerve examination.
3. Complete eye examination including detailed fundus examination, classifying expected eye problems as:

* Cataract. - Glaucoma
* Cranial nerve affection
* Retinopathy either proliferative, non proliferative or macular oedema.
4. The following investigations will be done:

* Serum creatinine \& Blood Urea for estimation of glomerular filtration rate
* Glycated haemoglobin (HbA1c).
* lipogram.
* Complete blood count
* ECG

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Eye Diseases Renal Impairment Type2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

50 patients Type 2 Diabetes without renal impairment will be examined using fundoscope

fundoscope

Intervention Type DEVICE

Fundoscope for eye examination

Group B

25 patients Type 2 Diabetes with chronic kidney disease not on replacement therapy (stage I-IV) will be examined using fundoscope

fundoscope

Intervention Type DEVICE

Fundoscope for eye examination

Group C

25 patients Type 2 Diabetes with end stage renal disease on haemodialysis will be examined using fundoscope

fundoscope

Intervention Type DEVICE

Fundoscope for eye examination

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fundoscope

Fundoscope for eye examination

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 50 patients Type 2 Diabetes without renal impairment.
* 25 patients Type 2 Diabetes with chronic kidney disease not on replacement therapy. (stage I-IV)
* 25 patients Type 2 Diabetes with end-stage renal disease on haemodialysis

Exclusion Criteria

* patients with previous history of eye problems and any systemic disease.
* Type 1 Diabetics .
* Acute kidney injury in Diabetics.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role collaborator

Mohammed Ramadan Abdallah

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohammed Ramadan Abdallah

Principal Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lobna F El-Toony, MD

Role: STUDY_CHAIR

Assiut University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mohamed R Abdallah

Role: CONTACT

Phone: 00201011770935

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AssiutU MRAbdallah

Identifier Type: -

Identifier Source: org_study_id